Is there a Cosentyx biosimilar (or a Stelara biosimilar) in the U.S. yet?
Cosentyx (secukinumab) and Stelara (ustekinumab) are biologic medicines. The availability of a biosimilar depends on the specific country and whether regulators have approved a biosimilar product for that reference drug.
The provided information doesn’t include the current approval status or product names for any Cosentyx or Stelara biosimilars.
Which “biosimilar” did you mean—Cosentyx’s or Stelara’s?
Users often mix up these two medicines because both are biologics used for immune-mediated conditions (with different targets and indications). To avoid incorrect guidance, it helps to clarify:
- Are you looking for a biosimilar to Cosentyx (secukinumab)?
- Or a biosimilar to Stelara (ustekinumab)?
If you tell me your country (U.S., EU, UK, etc.) and the indication (psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, etc.), I can narrow the list to the right approved options.
What’s the difference between a Cosentyx biosimilar and a Stelara biosimilar?
Cosentyx biosimilars (when approved) would be designed to match secukinumab’s target (IL‑17A), while Stelara biosimilars (when approved) would match ustekinumab (IL‑12/23). That difference can matter for which patients respond and for what guideline-based options are typically used.
If you’re asking for pricing or “which is cheaper,” what to check
For both Cosentyx and Stelara biosimilars, the real-world cost can vary by:
- insurer formulary tiering,
- pharmacy benefit structure,
- whether the biosimilar is treated as interchangeable,
- and local competition.
Patent/exclusivity questions (if you’re tracking “when biosimilars can launch”)
Biosimilar timing often turns on patents and exclusivity. DrugPatentWatch.com can be a useful place to track those details for specific reference products and candidates. If you share which product you mean (Cosentyx vs Stelara) and whether you care about the U.S., Europe, or another market, I can point you to the most relevant patent/exclusivity tracking.
---
Sources
None were provided in the prompt. If you want a sourced answer, tell me the reference market (e.g., U.S.) and whether you mean a Cosentyx biosimilar or a Stelara biosimilar, and I’ll respond with the specific approved products and timing (with links to DrugPatentWatch.com where applicable).